A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome-Reference-Cited by-同舟云学术

A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome

Published:2013-05-23 Issue:5 Volume:22 Page:605-611
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care (Engl)

Author:

Daver N.¹,Vega-Ruiz A.¹,Kantarjian H.M.¹,Estrov Z.¹,Ferrajoli A.¹,Kornblau S.¹,Verstovsek S.¹,Garcia-Manero G.¹,Cortes J.E.¹

Affiliation:

1. Department of Leukaemia; The University of Texas MD Anderson Cancer Centre; Houston; TX; USA

Publisher

Wiley

Subject

Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ecc.12065/fullpdf

Reference44 articles.

1. The role of azacitidine in the treatment of myelodysplastic syndromes;Abdulhaq;Expert Opinion on Investigational Drugs,2007

2. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas;Ajani;Cancer Treatment Reports,1986

3. Treatment strategies in myelodysplastic syndromes;Atallah;Cancer Investigation,2008

4. Cytotoxicity and cell cycle specificity of homoharringtonine;Baaske;Antimicrobial Agents and Chemotherapy,1977

5. Allogeneic stem cell transplantation for myelodysplastic syndrome;Barrett;Seminars in Hematology,2008

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study;Journal of Clinical Oncology;2023-11-01

2. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms;Cancers;2023-07-27

3. Update and New Insights on Future Cancer Drug Candidates From Plant-Based Alkaloids;Frontiers in Pharmacology;2021-12-16

4. Adverse drug reactions of anticancer drugs derived from natural sources;Food and Chemical Toxicology;2019-01

5. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents;American Journal of Hematology;2018-11-15